Xeris Biopharma files New Jersey patent suits after KEVEYIS patent grant
XERS•Xeris Biopharma filed patent infringement suits in New Jersey federal court on Oct. 13, 2026, targeting proposed generic dichlorphenamide products after a patent covering KEVEYIS was issued. The company seeks injunctions, damages, enhanced damages, attorneys’ fees and costs.
1. Patent infringement suits
Xeris Biopharma filed the suits in New Jersey federal court on Oct. 13, 2026, after U.S. Patent No. 12,758,502 covering KEVEYIS (dichlorphenamide) was issued. The claims target proposed generic dichlorphenamide products, alleging infringement through making, selling or importing them. Xeris seeks injunctions, monetary and enhanced damages, attorneys’ fees and costs.
